GSK1265744 rapidly suppresses HIV and appears safe at selected dose

David Margolis, Glaxo SmithKline, at EACS 2013. Photo by Liz Highleyman,
Published: 20 October 2013

The experimental HIV integrase inhibitor GSK1265744 demonstrated rapid and potent antiviral activity and good tolerability for treatment-naive people in the LATTE study, according to a report at the 14th European AIDS Conference this week in Brussels.

Integrase inhibitors are among the most well tolerated antiretroviral medications. GSK1265744 (or GSK744 for short), being developed by GlaxoSmithKline, is similar to the recently approved dolutegravir. It is being tested both as a once-daily oral drug and as a long-acting injectable that may allow for once-monthly administration. A recently presented analysis of eight studies showed that it is safe with no notable safety concerns.

David Margolis from GlaxoSmithKline and colleagues evaluated the safety, tolerability and efficacy of GSK744 in previously untreated people with HIV.

The phase 2b LATTE trial started with a 24-week induction phase comparing three oral doses of GSK744 plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) to inform selection of an optimal dose for further development. At week 24, participants with stable viral suppression discontinued NRTIs and switched to a simplified dual maintenance regimen of GSK744 plus oral rilpivirine (Edurant).

The primary endpoint of this partially blinded, dose-ranging, multicentre study is undetectable HIV viral load (<50 copies/ml) at 48 weeks. Margolis reported interim 24-week findings.

This analysis included 243 treatment-naive participants. Almost all were men; Margolis explained that the lack of women was in part due to a restriction on use of hormonal contraception since drug interactions with GSK744 are not yet known. A majority of participants (about 60%) were white, about 30% were black and the median age was about 34 years. The median CD4 cell count was approximately 410 cells/mm3 and 16% had high baseline viral load (>100,000 copies/ml). About 5% were co-infected with hepatitis C.

Participants were randomly assigned to receive GSK744 at doses of 10mg, 30mg or 60mg, or 600mg efavirenz, all once daily. They also started on two investigator-selected NRTIs, about 60% taking tenofovir/emtricitabine (Truvada) and 40% taking abacavir/lamivudine (Kivexa).

At 24 weeks, 87% of participants taking GSK744 achieved undetectable viral load (all dose arms combined) compared with 74% of those taking efavirenz in a 'snapshot' analysis. Response was similar with all GSK744 doses (88, 85 and 87%). There was no significant difference according to NRTI backbone.

Viral load fell rapidly after starting treatment in all GSK744 dose groups. People taking GSK744 achieved viral suppression significantly sooner than those taking efavirenz, with 76 vs 24%, respectively, having undetectable HIV RNA by week 4.

CD4 cell gains were similar for GSK744 and efavirenz recipients at week 24 (185 and 159 cells/mm3), though the increase was faster in the GSK744 arms (123 vs 59 cells/mm3 at week 8).

Virological failure rates in the snapshot analysis were 6% with GSK744 (all arms combined) and 15% with efavirenz. Protocol-defined virological failure – the narrower criteria used to determine who was eligible for the maintenance phase – was uncommon, with six total cases: one in each GSK744 dose arm (2% combined) and three in the efavirenz arm (5%). All these patients underwent genotypic or phenotypic resistance testing and no integrase, NRTI or NNRTI mutations were detected.

People taking GSK744 were about half as likely to withdraw from the study as those taking efavirenz (12 vs 26%), with no notable differences across GSK744 dose groups. This was mainly driven by a significantly lower dropout rate due to adverse events amongst GSK744 recipients (2 vs 11%, respectively).

Overall rates of grade 2 to 4 adverse events were similar, 18% with GSK744 and 16% with efavirenz. As expected, people taking efavirenz had more neuropsychiatric or central nervous system side-effects. Headache, usually mild to moderate, was more common with GSK744 (<3 vs 0%). Six people taking GSK744 had serious adverse events (none considered drug-related), as did three people taking efavirenz (one deemed drug-related, a suicide attempt).

Laboratory abnormalities occurred with similar frequency amongst GSK744 and efavirenz recipients overall. However, abnormalities were more common with the highest GSK744 dose. One-quarter of people in the 60mg group developed ALT liver enzyme elevations; these were usually mild, but there were two transient grade 4 (severe) elevations in people with pre-existing liver disease. Lipase elevation occurred in 8% in this arm but there were no cases of pancreatitis.

"Oral [GSK744] administered once daily with two NRTIs was associated with a good treatment response," the researchers concluded.

Based on these findings the 30mg GSK744 dose was selected. The maintenance phase of LATTE testing GSK744 plus rilpivirine maintenance therapy is currently underway. Results from that part of the trial will prepare the way for a phase 2b study of combined long-acting injectable formulations of both drugs, which may one day be used as monthly maintenance therapy or pre-exposure prophylaxis (PrEP).


Margolis D et al. Once-daily oral GSK1265744 (GSK744) as part of combination therapy in antiretroviral naive adults: 24-week safety and efficacy results from the LATTE study (LAI116482). 14th European AIDS Conference, Brussels, abstract PS7/1, 2013. View abstract on the EACS website.

NAM's coverage of the 14th European AIDS Conference has been made possible thanks to support from the European AIDS Clinical Society (EACS) and Merck & Co., Inc.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.